Fresenius Medical Care AG (NYSE:FMS)‘s stock had its “neutral” rating reiterated by analysts at DZ Bank AG in a report released on Thursday.

Other equities research analysts have also issued research reports about the stock. Berenberg Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, August 9th. HSBC reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, October 18th. RBC Capital Markets reaffirmed a “sector perform” rating and set a $44.00 price target (up previously from $41.00) on shares of Fresenius Medical Care AG in a research report on Tuesday, November 1st. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Fresenius Medical Care AG in a research report on Wednesday, September 21st. Finally, Citigroup Inc. raised shares of Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a report on Tuesday, September 6th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $45.33.

Analyst Recommendations for Fresenius Medical Care AG (NYSE:FMS)

Shares of Fresenius Medical Care AG (NYSE:FMS) opened at 39.85 on Thursday. The company has a market capitalization of $24.40 billion, a price-to-earnings ratio of 20.81 and a beta of 0.58. The firm’s 50-day moving average is $41.85 and its 200 day moving average is $43.32. Fresenius Medical Care AG has a 12 month low of $38.71 and a 12 month high of $47.52.

Fresenius Medical Care AG (NYSE:FMS) last released its quarterly earnings results on Thursday, October 27th. The company reported $1.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.57. Fresenius Medical Care AG had a net margin of 6.67% and a return on equity of 10.56%. The firm earned $4.60 billion during the quarter, compared to analyst estimates of $4.55 billion. During the same quarter in the prior year, the firm earned $0.93 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. Equities analysts expect that Fresenius Medical Care AG will post $2.02 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Cambiar Investors LLC increased its position in Fresenius Medical Care AG by 5.2% in the second quarter. Cambiar Investors LLC now owns 2,333,733 shares of the company’s stock valued at $101,681,000 after buying an additional 114,840 shares during the last quarter. Genesee Valley Trust Co. increased its position in Fresenius Medical Care AG by 3.4% in the second quarter. Genesee Valley Trust Co. now owns 7,712 shares of the company’s stock valued at $336,000 after buying an additional 253 shares during the last quarter. Bank of Montreal Can acquired a new position in Fresenius Medical Care AG during the second quarter valued at $2,638,000. Checchi Capital Advisers LLC increased its position in Fresenius Medical Care AG by 5.5% in the second quarter. Checchi Capital Advisers LLC now owns 3,449 shares of the company’s stock valued at $150,000 after buying an additional 179 shares during the last quarter. Finally, Telemus Capital LLC increased its position in Fresenius Medical Care AG by 8.2% in the second quarter. Telemus Capital LLC now owns 5,681 shares of the company’s stock valued at $248,000 after buying an additional 429 shares during the last quarter. Institutional investors and hedge funds own 2.49% of the company’s stock.

About Fresenius Medical Care AG

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Stock Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related stocks with our FREE daily email newsletter.